HOW WE HELP
NET Cancer is the FASTEST growing class of CANCER worldwide
HELP US HELP OTHERSNEUROENDOCRINE TUMOURS (NETs) OVERVIEW
-
Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
-
NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
-
NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
-
NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
-
The cause of NETs is currently unknown.
CNETS NEWS
From Gallstones to Cancer: A Mother’s Journey with NETs
Our amazing Hamilton/Halton /Niagara NET Support Group Leader, Vannesa Mann, shares her inspirational story! Zoomer | September 10th, 2021 For people with neuroendocrine tumours, early diagnosis and timely access to approved treatments [...]
Pewter Zebra Keyfobs/Pendants
Volunteers create one-of-a-kind handmade Pewter Zebra Keyfobs/Pendants to help raise awareness & funds for CNETS Al Gillis is a neuroendocrine cancer patient and member of the Toronto Patient and Caregiver support group. One of [...]
Temozolomide Access in Ontario
CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to Ontario-based neuroendocrine tumour (NET) patients. [...]
Lutathera Funded in Saskatchewan
As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced radiographic disease progression during somatostatin [...]
COVID-19 VACCINE & NEUROENDOCRINE CANCER PATIENTS
Disclaimer: CNETS is a patient organization, and we are unable to provide medical advice. Any information or guidance contained herein should not replace personalized medical advice. Our objective is to provide you with general [...]
LUTATHERA Funded In British Columbia
CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide Receptor Radionuclide Therapy (PRRT) using [...]
CNETS PRIORITIES
SUPPORT
- In-person peer-led support groups meetings
- Dedicated patient email and phone support
- Online private support groups for patients & caregivers
EDUCATION
- Patient and caregiver education sessions across Canada
- Robust online patient educational resources
- Printed educational resources including the NET Reference Guide
- Annual NET Medical and Scientific Meeting
AWARENESS
- Raise awareness of NET cancer to the general public & the medical community
- Participate in World NET Cancer Day Activities
